The role of alprazolam for the treatment of panic disorder in Australia
- PMID: 22391278
- DOI: 10.1177/0004867411432074
The role of alprazolam for the treatment of panic disorder in Australia
Abstract
Objective: To investigate the potential impact of increasing prescription rates of alprazolam for the treatment of panic disorder (PD) in Australia through a review of efficacy, tolerability and adverse outcome literature.
Methods: Data were sourced by a literature search using MEDLINE, Embase, PsycINFO and a manual search of scientific journals to identify relevant articles. Clinical practice guidelines from the American Psychiatric Association, National Institute of Clinical Excellence, Royal Australian and New Zealand College of Psychiatrists and World Federation of Societies of Biological Psychiatry were sourced. Prescription data were sourced from Australian governmental sources.
Results: Alprazolam has shown efficacy for control of PD symptoms, particularly in short-term controlled clinical trials, but is no longer recommended as a first-line pharmacological treatment due to concerns about the risks of developing tolerance, dependence and abuse potential. Almost no evidence is available comparing alprazolam to current first-line pharmacological treatment. Despite this, prescription rates are increasing. A number of potential issues including use in overdose and impact on car accidents are noted. conclusion: Although effective for PD symptoms in clinical trials, a number of potential issues may exist with use. Consideration of its future place in PD treatment in Australia may be warranted.
Comment in
-
Reconsidering benzodiazepines in the treatment of panic disorder.Aust N Z J Psychiatry. 2012 Mar;46(3):271-2. doi: 10.1177/0004867411433969. Epub 2012 Jan 5. Aust N Z J Psychiatry. 2012. PMID: 22391285 No abstract available.
-
Commentary on 'The role of alprazolam for the treatment of panic disorder in Australia'.Aust N Z J Psychiatry. 2012 Mar;46(3):273-4. doi: 10.1177/0004867412437169. Aust N Z J Psychiatry. 2012. PMID: 22391286 No abstract available.
Similar articles
-
The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder.J Clin Psychopharmacol. 2011 Oct;31(5):647-52. doi: 10.1097/JCP.0b013e31822d0012. J Clin Psychopharmacol. 2011. PMID: 21869686
-
Cognitive style, alprazolam plasma levels, and treatment response in panic disorder.Depress Anxiety. 2008;25(8):E18-26. doi: 10.1002/da.20403. Depress Anxiety. 2008. PMID: 17960759
-
Panic disorder: long-term pharmacotherapy and discontinuation.J Clin Psychopharmacol. 1998 Dec;18(6 Suppl 2):12S-18S. doi: 10.1097/00004714-199812001-00004. J Clin Psychopharmacol. 1998. PMID: 9872708 Review.
-
Efficacy studies of alprazolam in panic disorder.Psychopharmacol Bull. 1998;34(2):191-5. Psychopharmacol Bull. 1998. PMID: 9640999 Review.
-
A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature.J Clin Psychiatry. 1993 Oct;54 Suppl:25-45; discussion 46-8. J Clin Psychiatry. 1993. PMID: 8262888 Review.
Cited by
-
Pneumonia Risk Associated with the Use of Individual Benzodiazepines and Benzodiazepine Related Drugs among the Elderly with Parkinson's Disease.Int J Environ Res Public Health. 2021 Sep 6;18(17):9410. doi: 10.3390/ijerph18179410. Int J Environ Res Public Health. 2021. PMID: 34501996 Free PMC article.
-
Psychotropic medicine utilization in older people in New Zealand from 2005 to 2013.Drugs Aging. 2014 Oct;31(10):755-68. doi: 10.1007/s40266-014-0205-1. Drugs Aging. 2014. PMID: 25204576
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
